Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:

NCT ID: NCT05014646 Recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Start date: March 7, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.

NCT ID: NCT05014412 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

MagnetisMM-9
Start date: October 7, 2021
Phase: Phase 2
Study type: Interventional

The purpose of the study (Part 1 and Part 2) is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment or has not responded to treatment (relapsed/refractory multiple myeloma). This study will also look at the safety and efficacy of different doses of elranatamab, as well as different intervals between doses. Participants in the study will receive elranatamab as an injection under the skin at the study clinic. After the initial step-up doses, participants will start receiving one dose every week. The frequency of clinic visits for injections may then decrease over time. Participation will be at least two years.

NCT ID: NCT05013437 Withdrawn - Multiple Myeloma Clinical Trials

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

AHCT
Start date: September 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to see if Multiple Myeloma (MM) cells are sensitive to the chemotherapy used in transplant or not. The main chemotherapy agent utilized in stem cell transplant is melphalan. The study will utilize 1/10 of the dose used in transplant to study sensitivity of the tumor to melphalan. Melphalan is approved by the U.S. Food and Drug Administration (FDA) for transplant for MM patients.

NCT ID: NCT05013190 Recruiting - Multiple Myeloma Clinical Trials

A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Start date: October 29, 2021
Phase:
Study type: Observational

The main aim of this study is to check side effects and results in adults with multiple myeloma after switching from a bortezomib-based to an Ixazomib-based treatment. Treatment with NINLARO® will strictly follow the product label.

NCT ID: NCT05011097 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Start date: July 8, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this Phase I study is to access the safety and tolerability of Y150 at different dose levels. It is hoped to find out the recommended dose for Phase II/III.

NCT ID: NCT05011045 Recruiting - Lymphoma Clinical Trials

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Start date: January 9, 2020
Phase:
Study type: Observational

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.

NCT ID: NCT05008536 Recruiting - Clinical trials for Multiple Myeloma, Refractory

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Start date: October 1, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to infuse BCMA CAR-NK cells(Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells) to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.

NCT ID: NCT05007652 Completed - Clinical trials for Multiple Myeloma and Malignant Lymphoma

A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.

NCT ID: NCT05007418 Recruiting - Multiple Myeloma Clinical Trials

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Start date: October 1, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

NCT ID: NCT05006469 Recruiting - Multiple Myeloma Clinical Trials

Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

Start date: June 1, 2021
Phase: Phase 3
Study type: Interventional

Observe the best dose, efficacy and adverse reactions of BAd in the treatment of relapsed and refractory multiple myeloma.